[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Zee C O N T R A R I A N [@ZeeContrarian1](/creator/twitter/ZeeContrarian1) on x 28.8K followers Created: 2025-06-10 15:04:20 UTC The Catalyst Lineage’s market value is just $XXX million. With early 3-year trial results coming in June 20-21, lasting vision improvements could attract investor attention, push Roche to move faster, and quickly re-rate the stock. This is an open-label study, meaning both doctors and patients know who received the treatment. It’s hard to imagine Roche—one of the world’s most sophisticated drug developers—sending a top retinal surgeon to deliver bad news at a major international conference. If the results were poor, they simply wouldn’t be presenting them on a global stage. The fact that this data is being featured at CTS 2025, with Roche’s name on it, strongly suggests they believe the 3-year results are worth showing — and potentially very positive.  XXXXX engagements  **Related Topics** [faster](/topic/faster) [investment](/topic/investment) [zee](/topic/zee) [Post Link](https://x.com/ZeeContrarian1/status/1932453785193812077)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Zee C O N T R A R I A N @ZeeContrarian1 on x 28.8K followers
Created: 2025-06-10 15:04:20 UTC
The Catalyst
Lineage’s market value is just $XXX million. With early 3-year trial results coming in June 20-21, lasting vision improvements could attract investor attention, push Roche to move faster, and quickly re-rate the stock.
This is an open-label study, meaning both doctors and patients know who received the treatment.
It’s hard to imagine Roche—one of the world’s most sophisticated drug developers—sending a top retinal surgeon to deliver bad news at a major international conference.
If the results were poor, they simply wouldn’t be presenting them on a global stage. The fact that this data is being featured at CTS 2025, with Roche’s name on it, strongly suggests they believe the 3-year results are worth showing — and potentially very positive.
XXXXX engagements
Related Topics faster investment zee